JP2025508071A5 - - Google Patents
Info
- Publication number
- JP2025508071A5 JP2025508071A5 JP2024553437A JP2024553437A JP2025508071A5 JP 2025508071 A5 JP2025508071 A5 JP 2025508071A5 JP 2024553437 A JP2024553437 A JP 2024553437A JP 2024553437 A JP2024553437 A JP 2024553437A JP 2025508071 A5 JP2025508071 A5 JP 2025508071A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317483P | 2022-03-07 | 2022-03-07 | |
| US63/317,483 | 2022-03-07 | ||
| PCT/IB2023/052082 WO2023170547A1 (en) | 2022-03-07 | 2023-03-06 | Pure forms of crystalline aticaprant |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025508071A JP2025508071A (ja) | 2025-03-21 |
| JPWO2023170547A5 JPWO2023170547A5 (https=) | 2026-02-17 |
| JP2025508071A5 true JP2025508071A5 (https=) | 2026-02-17 |
Family
ID=85979414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553437A Pending JP2025508071A (ja) | 2022-03-07 | 2023-03-06 | 純粋な形態の結晶質アチカプラント |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20230348377A1 (https=) |
| EP (1) | EP4489748A1 (https=) |
| JP (1) | JP2025508071A (https=) |
| KR (1) | KR20240158951A (https=) |
| CN (1) | CN119156210A (https=) |
| AU (1) | AU2023231493A1 (https=) |
| CA (1) | CA3254503A1 (https=) |
| CL (1) | CL2024002643A1 (https=) |
| CO (1) | CO2024012457A2 (https=) |
| IL (1) | IL315411A (https=) |
| JO (1) | JOP20240195A1 (https=) |
| MX (1) | MX2024010978A (https=) |
| PE (1) | PE20242109A1 (https=) |
| TW (1) | TW202345795A (https=) |
| WO (1) | WO2023170547A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| WO2023170554A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Compositions comprising aticaprant |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| CN117903050B (zh) * | 2024-03-15 | 2024-05-17 | 中国药科大学 | 阿立哌唑共晶及其药物组合物和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5345637B2 (ja) * | 2008-01-22 | 2013-11-20 | イーライ リリー アンド カンパニー | κ選択的オピオイド受容体アンタゴニスト |
| US10316021B2 (en) * | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| PH12023552963A1 (en) * | 2021-05-04 | 2024-03-11 | Janssen Pharmaceuticals Inc | Compositions and methods for the treatment of depression |
-
2023
- 2023-03-06 AU AU2023231493A patent/AU2023231493A1/en active Pending
- 2023-03-06 CA CA3254503A patent/CA3254503A1/en active Pending
- 2023-03-06 TW TW112108147A patent/TW202345795A/zh unknown
- 2023-03-06 EP EP23715931.4A patent/EP4489748A1/en active Pending
- 2023-03-06 JP JP2024553437A patent/JP2025508071A/ja active Pending
- 2023-03-06 KR KR1020247033036A patent/KR20240158951A/ko active Pending
- 2023-03-06 US US18/179,025 patent/US20230348377A1/en not_active Abandoned
- 2023-03-06 IL IL315411A patent/IL315411A/en unknown
- 2023-03-06 WO PCT/IB2023/052082 patent/WO2023170547A1/en not_active Ceased
- 2023-03-06 CN CN202380038807.1A patent/CN119156210A/zh active Pending
- 2023-03-06 PE PE2024001920A patent/PE20242109A1/es unknown
-
2024
- 2024-09-03 CL CL2024002643A patent/CL2024002643A1/es unknown
- 2024-09-05 JO JOJO/P/2024/0195A patent/JOP20240195A1/ar unknown
- 2024-09-06 MX MX2024010978A patent/MX2024010978A/es unknown
- 2024-09-13 CO CONC2024/0012457A patent/CO2024012457A2/es unknown
-
2025
- 2025-06-30 US US19/254,965 patent/US20250326714A1/en active Pending